November 9, 2009
Volcano
Corporation Presentation at Canaccord Adams Conference
to Be Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacture
and sales of products for the diagnosis and treatment of coronary and peripheral
artery disease, said today that it will be participating in the Third Annual
Canaccord Cardiovascular Conference on Tuesday, November 10. (Read
more...)
November 5, 2009
Volcano Reports
22 Percent Increase in Third Quarter Revenues
Volcano Corporation (Nasdaq: VOLC) today reported revenues of $53.9 million
for the third quarter of fiscal 2009.
The results for the quarter ended September 30, 2009, represent an increase of
22 percent over revenues of $44.1 million in the third quarter of 2008. (Read
more...)
September 24, 2009
Results
From Landmark PROSPECT Trial Demonstrate the Ability of
Volcano's VH® IVUS Imaging to Identify Plaques Most Likely
to Cause Heart Attacks
PROSPECT results presented today include the landmark finding that angiographically
mild lesions with certain morphologic features on grayscale and VH IVUS present
with a 3 year cardiac event rate of 17%, versus other morphologies (indistinguishable
by conventional angiograms) with three year event risks of less than 1%. (Read
more...)
September 23, 2009
Volcano
Corporation Praises FAME Study Results
The results of the prospective, multi-center trial at 12-months, originally
published in the New England Journal of Medicine in 2009, demonstrate that
patients with multi-vessel coronary artery disease who were treated by FFR
guidance had a 34% reduction in death and myocardial infarction (MI) compared
to angiographic guidance alone. The clinical benefit of FFR-guidance at two
years showed the sustained reduction in death and heart attacks of 34%. (Read
more...)
September 10, 2009
Volcano
Corp. Announces Events at TCT Meeting
Volcano Corporation (Nasdaq: VOLC), a leader in the fields of Intravascular
Ultrasound (IVUS) and Functional Measurement (FM) today announced a wide variety
of events taking place at this year's Transcatheter Cardiovascular Therapeutics
(TCT) meeting in San Francisco. A wide spectrum of activities will demonstrate
how these technologies can improve the results obtained from angioplasty and
stenting, and includes late-breaking clinical trials, symposia with panels
of experts, live case demonstrations and an investor event. (Read
more...)
September 1,
2009
Volcano
Corporation Presentation at Weisel Conference to be Webcast
Volcano Corporation said today that it will be participating in the Thomas
Weisel Partners Healthcare Conference 2009 on Wednesday, September 9.
The presentation by John Dahldorf, chief financial officer, will begin at 8 a.m.,
Eastern Daylight Time (5 a.m., Pacific Daylight Time). (Read
more...)
August 25, 2009
Volcano
Corporation and Siemens Healthcare Announce Global Resale
Agreement for Volcano IVUS/FFR Systems
Volcano Corporation (Nadsaq: VOLC), announced today that it has entered into
a non-exclusive, global resale agreement with Siemens Healthcare, a sector
of Siemens AG (NYSE: SI). Under this agreement, Siemens will resell Volcano-branded
s5i IVUS/FFR systems and accessories alongside Siemens' Artis family of X-ray
systems. (Read
more...)
August 7, 2009
Volcano
Corporation Presentation At Canaccord Adams Conference
To Be Webcast
Volcano Corporation (Nadsaq: VOLC), a leader in the development, manufacturing
and sales of products for the diagnosis and treatment of coronary and peripheral
artery disease, said today that it will be participating in the Canaccord Adams
29th Annual Global Growth Conference on Thursday, August 13. (Read
more...)
August 4, 2009
Volcano Reports
30 Percent Increase in Second Quarter Revenues
Volcano's CEO Scott
Huennekens states, "IVUS disposable revenues in the quarter were $31.8 million,
a record quarter for this business, and a 26 percent increase over the second
quarter a year
ago. FM revenues in the quarter were a record $7.2 million, with FM disposable
revenues increasing 75 percent over the second quarter a year ago. In addition,
we continued our successful IVUS/FM console placement initiatives, placing
233 consoles versus 178 a year ago, an increase of 31 percent.... These results
portray the value of our technology innovation, effective sales and marketing
programs and the growing recognition among clinicians that IVUS and FM can
play an important role in the diagnosis
and treatment of patients. (Read
more...)
July 27, 2009
Volcano
Corporation Schedules Second Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC) will hold a conference call to discuss its
financial results and operating activities open to all interested parties at
2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time), Tuesday, August
4, hosted by Scott Huennekens, president and chief executive officer, and John
Dahldorf, chief financial officer. (Read
more...)
July 8, 2009
Volcano Achieves
Major Milestone in Japan Direct Sales Initiative With Signing
of Termination Agreement With Goodman
Volcano Corporation said today it has signed a termination
agreement with its largest distributor in Japan, Goodman Company, Ltd. This
agreement, which took effect today, will enable Volcano to accelerate
its transition to a direct sales force in the market to support its
intravascular ultrasound (IVUS) and Functional Measurement (FM) consoles
and disposables, as well as products currently in development. (Read
more...)
July 5, 2009
Interview
with Giulio Guagliumi, MD About Optical Coherence Tomography
and Stents
Dr. Giulio Guagliumi, an internationally recognized leader in the use of Optical
Coherence Tomography (OCT) in the coronary arteries, practices in the Cardiovascular
Department of Ospedali Riuniti di Bergamo in Bergamo, Italy. Dr. Guagliumi
has been published in numerous peer-reviewed journals and is principal investigator
in several clinical trials assessing the performance of stents inside the coronary
artery, using OCT imaging. In this interview, he discusses the dynamic changes
occurring with this technology. (Read
more...)
May 25, 2009
Meeting
to Highlight Use of New Imaging Technologies for Guiding
Stent and Angioplasty Procedures
This week marks one of the first courses to focus exclusively on the range
of innovative intravascular imaging and measurement technologies that have
been gaining in use over the past couple of years. "OCT, IVUS, FFR: When, Where,
How" will be held on May 28 and 29 in Bergamo, Italy. The course will utilize
the newest innovations in Optical Coherence Tomography(OCT), Intravascular
Ultrasound (IVUS), Virtual Histology (VH) and Fractional Flow Reserve (FFR)
and how they can be used to optimize percutaneous procedures, such as angioplasty
and stenting. (Read
more...)
May 19, 2009
Optical Coherence
Tomography (OCT) Presentations by Volcano at EuroPCR 2009
Volcano Corporation (Nasdaq: VOLC) today highlights its technology leadership
position in the emerging field of Optical Coherence Tomography (OCT) at the
EuroPCR conference in Barcelona, Spain. Volcano's wholly owned subsidiary,
Axsun, has developed what we believe to be a truly revolutionary new class
of ultra-miniaturized external cavity lasers that are expected to power the
highest performance OCT systems for intracoronary and other medical imaging
segments. (Read more...)
May 19, 2009
New
Intravascular Ultrasound (IVUS) Study of Underexpanded
Stents, Thrombosis and Restenosis
A study, published in the current issue of JACC Interventions, details 120
drug-eluting stent cases as viewed by intravascular ultrasound (IVUS) in order
to examine characteristics that may lead to in-stent restenosis (ISR) or stent
thrombosis. The researchers found that in cases of thrombosis, the proximal
parts of many of the stents were inadequately expanded. An accompanying editorial
suggests greater use of IVUS and more attention to detail can reduce the number
of these adverse clinical events. (Read
more...)
May 18, 2009
Volcano
Announces Worldwide Exclusive Distribution Agreement With
Lumen Biomedical for Xtract™ Thrombus Aspiration
Catheter
Volcano Corporation (Nasdaq: VOLC) today announced an exclusive worldwide distribution
agreement to initiate the formal launch of the Xtract™ thrombus aspiration
catheter, manufactured by Lumen Biomedical. The Xtract thrombus aspiration
catheter is available for immediate sale in the U.S. and Europe. This marks
Volcano's entry into what some believe is a $70+ million aspiration market. (Read
more...)
May 13, 2009
Volcano
Corporation Presentation at JMP Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating
in the Eighth Annual JMP Securities Research Conference on Monday, May 18.
The presentation by John Dahldorf, chief financial officer, will begin at 3:00
p.m., Pacific Daylight Time (6:00 p.m., Eastern Daylight Time). (Read
more...)
May 6, 2009
Volcano
Corporation Presentation at Bank of America/Merrill Lynch
Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating
in the Bank of America and Merrill Lynch 2009 Health Care Conference on Thursday,
May 14. The presentation by Scott Huennekens, president and chief executive
officer, will begin at 11:20 a.m., Eastern Daylight Time (8:20 a.m., Pacific
Daylight Time). (Read
more...)
May 5, 2009
Volcano
Reports 1st Quarter Revenues of $49 Million; IVUS and FM
Businesses Grew 24%
Volcano Corp. (VOLC) reports a greater loss over the same period in 2008, due
mainly to lower margins and the strength of the dollar. However, revenue of
intravascular ultrasound and functional measurement products grew 24%. (Read
more...)
May 4, 2009
Effectiveness
in Stenting
As Volcano's CEO Scott Huennekens writes in an op-ed piece, there's a whole
toolbox of devices and techniques that are candidates for "comparative effectiveness" in
that they may be able to increase the success of interventional procedures
-- or even target patients who need these procedures more accurately. (Read
more...)
April 27, 2009
Volcano
Corporation Schedules First Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing
and sales of products for the diagnosis and treatment of coronary and peripheral
artery disease, today announced that it will report its operating results for
the first quarter of fiscal 2009 on Tuesday, May 5. (Read
more...)
March 27, 2009
Volcano
Announces the Availability of Integrated Fractional Flow
Reserve Technology on All Major Cardiovascular X-ray Angiography
Systems
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing
and sales of products for the diagnosis and treatment of coronary and peripheral
artery disease, today announced the availability of its integrated Fractional
Flow Reserve (FFR) technology on all major cardiovascular x-ray systems: GE,
Philips, Siemens and Toshiba. (Read
more...)
March 27, 2009
Volcano
Announces Schedule of Events at the ACC 2009, Integration
into Indec and Medis Software Platforms
Joe Burnett, Vice President of Marketing at Volcano commented, "Three years
ago, you could flip through the ACC program and see a couple of presentations
on intravascular assessment using IVUS or FFR. This year, there are more than
50 presentations, case reviews and abstracts focused on FFR, IVUS, OCT, Forward-Looking
IVUS, and VH® IVUS plaque composition. Word is getting out that more precise
guidance during PCI is important, and the sheer number of talks focused on
higher resolution tools, highlight the increased demand for access to these
technologies. (Read
more...)
March 26, 2009
ACC
2009 Sessions on Intravascular Imaging and Functional Measurement
The upcoming American College of Cardiology Annual Scientific Sessions, being
held in Orlando, Florida from March 28-31 is featuring more than 50 presentations,
case reviews and abstracts focused on intravascular imaging and functional
measurement modalities, such as Fractional Flow Reserve (FFR), Intravascular
Ultrasound (IVUS, Optical Coherence Tomography (OCT), as well as newer technologies,
like Forward-Looking IVUS and VH plaque composition. (Read
more...)
February 20, 2009
Volcano
Corporation Announces Webcast of February 25th Analyst
Day
Volcano Corporation (Nasdaq: VOLC) will hold its 2009 Analyst Day on Wednesday,
February 25, at the NASDAQ MarketSite in New York City. The webcast will begin
at 10 a.m., Eastern Standard Time (7 a.m., Pacific Standard Time) and conclude
at 2 p.m., Eastern Standard Time (11 a.m., Pacific Standard Time). (Read
more...)
February 17, 2009
Volcano
Reports Full Year Revenues Increase 31 Percent
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing
and sales of products for the diagnosis and treatment of coronary and peripheral
artery disease, today reported that revenues for the full year 2008 increased
31 percent over full year 2007 and that revenues for the fourth quarter of
2008 increased 23 percent over revenues in the fourth quarter of 2007. (Read
more...)
February 12, 2009
Volcano
CEO to Present at Roth Capital Partners Conference; Webcast
Announced
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing
and sales of products for the diagnosis and treatment of coronary and peripheral
artery disease, said today that it will be participating in the Roth Capital
Partners 21st Annual Growth Stock Conference on Wednesday, February 18. (Read
more...)
February 6, 2009
Volcano Corporation
Schedules Fourth Quarter Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development,
manufacturing and sales of products for the diagnosis and treatment
of coronary and peripheral artery disease, today announced that
it will report is operating results for the fourth quarter and
all of fiscal 2008 on Tuesday, February 17. (Read more...)
January 20, 2009
Volcano
Highlights Commitment, Market Acceptance of FFR Product
Line
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing
and sales of products for the diagnosis and treatment of coronary and peripheral
artery disease, today commented on the increased demand for their FFR and IVUS
capable consoles, as well as their FFR pressure guide wires. Since announcement
of the FAME study results at the TCT in October, the FFR option for Volcano's
s5i integrated imaging console was included in more than 90% of all new orders. (Read
more...)
January 17, 2009
FAME: "Back
to the Future"
The leading story about stents this past week has been the publication of the
FAME study and how a new St. Jude Medical device that measures blood pressures
inside the artery can reduce the number of unnecessary angioplasty and stent
procedures. Well...it's not a new device; it's definitely not a new concept;
and St. Jude doesn't exactly get the credit for it either, since their chief
role was to acquire the company that created the product. But it is an important
study! (Read
more...)
January 15, 2009
Better
Outcomes for Stents When Fractional Flow Reserve (FFR)
is Used
One-third fewer stents were used in the FFR group and the difference in outcomes
at one year were significant: the FFR group showed a 28% lower incidence of
major adverse cardiac events (repeat procedure to open the artery, heart attack
or death) -- 18.3% vs. 13.2%. The implication in these results is that placing
stents in lesions that are not responsible for ischemia is not only not necessary,
but may cause worse outcomes. (Read
more...)
January 15, 2009
Interview
with Nico H. J. Pijls, MD, PhD
Angioplasty.Org conducts an exclusive interview with Dr. Nico Pijls, co-principal investigator of the FAME study (Fractional Flow Reserve vs. Angiography
for Multivessel Evaluation) published today in the New England Journal
of Medicine.
The study concludes that "Routine measurement of FFR in patients with multivessel
coronary artery disease who are undergoing PCI with drug-eluting stents significantly
reduces the rate of the composite end point of death, nonfatal myocardial infarction,
and repeat revascularization at 1 year." (Read
more...)
January 7, 2009
Volcano
Announces Closing of Axsun Technologies Acquisition
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing
and sales of products for the diagnosis and treatment of coronary and peripheral
artery disease, said today that it has closed its previously announced acquisition
of Axsun Technologies, Inc. (Read more...)
January 6, 2009
Volcano
Corporation Presentation at J.P. Morgan Conference to be
Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing
and sales of products for the diagnosis and treatment of coronary and peripheral
artery disease, said today that it will be participating in the 27th Annual
J.P. Morgan Healthcare Conference on Wednesday, January 14. (Read
more...)
December 23, 2008
Volcano Announces
Acquisition of Axsun Technologies, Inc.
Volcano Corporation said today that it has entered into a definitive agreement
to acquire Axsun Technologies, Inc., a privately-held company that is a leading
developer and manufacturer of lasers and optical engines used in medical Optical
Coherence Tomography (OCT) imaging systems and advanced photonic components
and subsystems used in other industrial applications. (Read
more...)
December 9, 2008
Interview
with Szilard Voros, MD
Virtual Histology IVUS allows the cardiologist to see not only the plaque inside
the artery, but what the composition of that plaque is. We discuss this new
technology with one of the leading researchers in the field. (Read
more...)
December 2, 2008
Volcano
Corporation: Intravascular Imaging Ascending
In the midst of a recession, Volcano Corporation has shown a 19% increase in
its stock value over the past six months. Its only competitor in the U.S. market
suffered a 55% decrease. Why? (Read
more...)
November 24, 2008
Volcano
Corporation Presentation at Piper Jaffray Conference to
Be Webcast
Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing
and sales of products for the diagnosis and treatment of coronary and peripheral
artery disease, said today that it will be participating in the 20th Annual
Piper Jaffray Health Care Conference on Tuesday, December 2. (Read
more...)
November 5, 2008
78%
Increase in Intravascular Ultrasound Systems Sales Boosts
Volcano Quarterly Growth by 40%
For the quarter ended September 30, 2008, Volcano reported revenues of $44.1
million versus revenues of $31.5 million in the same period a year ago. The
company said that its financial performance was driven by a 78 percent increase
in intravascular ultrasound (IVUS) system revenues and a 29 percent increase
in IVUS disposable revenues year-over-year. (Read
more...)
November 5, 2008
Volcano
Corporation To Report Third Quarter Results Today During
Conference Call, Webcast
Volcano Corporation (Nasdaq: VOLC) will report its operating results for the
third quarter and first nine months of fiscal 2008 on Wednesday, November 5.
The company will hold a conference call to discuss its financial results and
operating activities open to all interested parties at 2 p.m., Pacific Standard
Time (5 p.m. Eastern Standard Time). (Read
more...)
October 22, 2008
ODESSA
Trial Looks Inside Drug-Eluting Stents With Optical Coherence
Tomography (OCT)
(Updated) The results of ODESSA showed that OCT could indeed accurately measure
strut coverage and NIH. An interesting data point was confirmation of the differences
in the currently available DES. ODESSA looked at Cypher, Taxus, Endeavor and
Bare Metal stents. The results showed that at six months, virtually all the
struts of the Endeavor stent were covered -- the healing was even more complete
than with bare metal stents, which reinforces reports of little or no very
late stent thrombosis with the Endeavor. At the same time, an inverse relationship
was observed between strut coverage and growth of neo-intimal hyperplasia (NIH)
-- the Endeavor had the highest NIH growth of the DES (also called Late Loss)
while the Cypher stent had the least Late Loss, but the highest number of uncovered
struts. (Read
more...)
October 15, 2008
Volcano
Corporation Announces Launch of PrimeWire™ Pressure
Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS
Consoles
Volcano Corporation (Nasdaq: VOLC) today announced the launch of the PrimeWire™ Pressure
Guidewire, and the s5-FFR Option for its existing installed base of s5 and
s5i imaging consoles in the U.S. The PrimeWire is Volcano's newest pressure
guidewire, capable of measuring pressure gradients across a lesion to determine
the ischemic nature of the stenosis, and can also help determine the extent
to which the blockage is flow-limiting. (Read
more...)
October 13, 2008
Volcano Corporation
Announces Schedule of Events for TCT (Transcatheter Cardiovascular
Therapeutics Conference) 2008
The company has announced a wide range of events including live case transmissions,
symposia to highlight new products and the clinical utility of Volcano technologies
including FFR, IVUS, VH IVUS, OCT and Forward-Looking IVUS (Read
more...)
October 6, 2008
Volcano Corporation
Relocating Corporate Headquarters to San Diego
The new corporate headquarters is located in the Carmel Valley area of San
Diego and now houses corporate executives, marketing, finance, accounting,
corporate human resources, legal and catheter engineering. The company intends
to expand its operations in San Diego in the future. The company's core research
and development, manufacturing, operations, quality and local human resources
functions will remain in Volcano's facilities in Rancho Cordova, CA. (Read
more...)
September 20, 2008
Volcano
Corporation Schedules Events for 2008 TCT Transcatheter
Cardiovascular Therapeutics Meeting
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer of intravascular
ultrasound (IVUS) and functional measurement (FM) technology, has scheduled
several events to be held during the 2008 TCT meeting in Washington DC, being
held October 12-17, 2008 at the Washington Convention Center. (Read
more...)
September 15, 2008
Volcano
Announces Resignation of Olav Bergheim from Board of Directors
The Company announced today that Olav B. Bergheim, the Volcano's chairman of
the
board,
will resign from the board of directors effective as of the close of business
on January 1, 2009. A co-founder of Volcano, Bergheim is the managing director
of Fjord Ventures LLC, a venture capital firm he founded, and has served as chairman
of Volcano's board since 2001. (Read
more...)
September 2,
2008
Volcano's
Virtual Histology Imaging Allows Major Drug Study (IBIS-2)
to Measure "Vulnerable Plaque"
Volcano's VH® IVUS technology is being used in an imaging study of GlaxoSmithKline's
novel investigational compound, Darapladib. Dubbed the IBIS-2 (Integrated
Biomarker and Imaging Study) the study results demonstrate the benefits
of VH® IVUS
in drug development. (Read
more...)
July 29, 2008
Volcano Corporation
Schedules Second Quarter Conference Call and Webcast
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of
intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence
Tomography (OCT) products designed to enhance the diagnosis and treatment of
coronary and peripheral vascular disease, today announced that it will report
its operating results for the second quarter and first six months of fiscal
2008 on Tuesday, August 5. (Read
more...)
July 8, 2008
Intravascular
Ultrasound (IVUS) May Reduce Drug-Eluting Stent Thrombosis
by a Third
A provocative study in the current issue of the European Heart Journal concludes
that: "IVUS guidance during DES implantation has the potential to influence
treatment strategy and reduce both DES thrombosis and the need for repeat revascularization." The
results were striking, surprising even the investigators. At 12 months, definite
stent thrombosis had occurred in 0.7% of the patients in whom intravascular
ultrasound guidance had been utilized, but in patients where IVUS was not used,
the stent thrombosis rate was 2.0%, almost three times higher. (Read
more...)
June 28, 2008
Interview
with Ron Waksman, MD, FACC
Our IVUS Center features a discussion about an important new study,
just published in the European Heart Journal, showing that IVUS guidance
can improve outcomes with drug-eluting stents, including significantly lower
rates
of stent thrombosis. (Read
more...)
June 3, 2008
When
Can I Stop Taking Plavix? -- A New Imaging Modality May Help
Patients and Physicians Determine Optimal Duration of Antiplatelet
Therapy in the Not-Too-Distant Future
(Updated) The question on the minds of a great
many patients who have had a drug-eluting stent implanted
is: "When can I stop taking Plavix? When will my drug-eluting
stent be completely healed?" It's THE question of the day,
and no one is really sure of the answer. However, a new
imaging technology, called Optical Coherence Tomography
or OCT, may help with this issue in the not-too-distant
future.. (Read
more...)
May 19, 2008
Volcano
Corporation Presentation at JMP Conference to be Webcast
Volcano Corporation (Nasdaq: VOLC), a provider of intravascular ultrasound
(IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT)
products designed to enhance the diagnosis and treatment of coronary and peripheral
vascular disease, said today that it will be participating in the Seventh Annual
JMP Securities Research Conference on Tuesday, May 20. (Read
more...)
May 19, 2008
Volcano
Announces Acquisition of Novelis, Inc.
Novelis' Forward-Looking IVUS technology platform is expected to enable Volcano
to offer an expanded line of minimally invasive diagnostic and therapeutic
devices, especially in the area of chronic total occlusions (CTO). (Read
more...)
May 15, 2008
Intravascular
Ultrasound (IVUS) Use Growing with Integration into Routine
Cath Lab Imaging
Intravascular Ultrasound, or IVUS, is an imaging technology that looks at arteries
from the inside out. Invented two decades ago, IVUS recently has been gaining
in usage due to safety concerns about stent thrombosis and proper stent placement
during angioplasty. (Read
more...)
May 12, 2008
Volcano
Announces Placement of 1,000th s5 and s5i IVUS Imaging
System; Presence at the EuroPCR08 will highlight choice
of different modalities available on single integrated
imaging platform
Scott Huennekens, President and Chief Executive Officer
of Volcano, commented, "Reaching
this milestone as quickly as we have is a clear indication of the clinical
adoption of IVUS and FFR, and the competitiveness of our product. More
and more physicians are using intravascular imaging to measure lesion
significance and improve PCI technique. The ease of use and flexibility
of our newest systems have been very well received. These new systems
are gaining traction with both new IVUS users, as well as those who are
looking to replace their legacy IVUS technology." (Read
more...)
May 8, 2008
Volcano
Corp Announces First Human Use of the Volcano Optical
Coherence Tomography (OCT) Imaging Catheter
Volcano Corporation (Nasdaq: VOLC) announced today the first human procedure
using the Volcano OCT Imaging catheter. The procedure was performed by
Dr. Patrick Serruys at the Thoraxcenter, in Rotterdam, Netherlands. Volcano
OCT will complement its existing line of IVUS imaging catheters and pressure
guidewires used for coronary imaging and lesion assessment. (Read
more...)
May 7, 2008
Volcano
Reports 24 Percent Increase in First Quarter Revenues;
IVUS Disposable Revenues Increase 30 Percent
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer
of intravascular ultrasound (IVUS), functional measurement (FM) and Optical
Coherence Tomography (OCT) products designed to enhance the diagnosis
and treatment of coronary and peripheral vascular disease, today reported
results for the first quarter of fiscal 2008. (Read
more...)
May 5, 2008
Volcano
Announces Participation in SATURN Clinical Trial Sponsored
by AstraZeneca
SATURN is a 104-week, parallel-group, multicentre, double-blind, Phase
IIIb intravascular ultrasound (IVUS) imaging study of approximately 1,300
patients at 170 centres This study by AstraZeneca is designed to measure
the impact of CRESTOR™ (rosuvastatin) 40 mg and atorvastatin (Lipitor®)
80 mg on the progression of atherosclerosis in high risk patients. SATURN
will compare the effects of these two statins on the ability to decrease
progression or induce regression of atherosclerosis, the main cause of
cardiovascular disease, following two years of treatment in patients
with coronary artery disease. (Read
more...)
April 29, 2008
Volcano
Corporation Schedules First Quarter Conference Call,
Webcast
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer
of intravascular ultrasound (IVUS), functional measurement(FM) and Optical
Coherence Tomography (OCT) products designed to enhance the diagnosis
and treatment of coronary and peripheral vascular disease, today announced
that it will report its operating results for the first quarter of fiscal
2008 on Wednesday, May 7. (Read
more...)
March 31, 2008
Volcano
Corporation Announces North America Resale Agreement
with Royal Philips Electronics
Volcano Corporation, leading manufacturer of intravascular ultrasound
(IVUS), announced today that it has entered into a non-exclusive, resale
agreement covering North America with Royal Philips Electronics. Under
this agreement, Philips will resell Volcano-branded s5i IVUS systems
and accessories alongside of the Philips Allura Xper FD X-ray systems. (Read
more...)
March 28, 2008
Volcano
Announces U.S. and European Launch of Rotational IVUS
and Integrated FFR
Volcano Corporation, a leading manufacturer and developer of intravascular
ultrasound (IVUS), functional measurement (FM) and Optical Coherence
Tomography (OCT) products designed to enhance the diagnosis and treatment
of coronary and peripheral vascular disease, announced today the U.S.
and European launch of the s5-Revo and s5-FFR (fractional flow reserve)
options for the s5i integrated Imaging platform. (Read
more...)
March 27, 2008
Intravascular
Ultrasound (IVUS) Events at American College of Cardiology
Annual Meeting
Intravascular ultrasound (IVUS) is scheduled to be part of 29 separate
sessions at this weekend's annual meeting of cardiologists in Chicago.
In addition, IVUS will be used by interventionalists who will be performing
14 live procedures, to be broadcast to the Convention Center at McCormick
Place from Lenox Hill Hospital in New York, and other medical centers
in California, London, Germany, Japan and Australia. (Read
more...)
March 12, 2008
Volcano
Corporation Presentation at Cowen Healthcare Conference
to be Webcast
Volcano Corporation (Nasdaq: VOLC), a leading provider of intravascular
ultrasound (IVUS) and functional measurement (FM) products designed to
enhance the diagnosis and treatment of coronary and peripheral vascular
disease, will be participating in the Cowen and Company 28th Annual Health
Care Conference on Monday, March 17. The presentation by president and
CEO, Scott Huennekens, will begin at 3:15 p.m., Eastern Daylight Time
(12:15 Pacific Daylight Time). (Read
more...)
February 12, 2008
Volcano
Reports 35% Increase in Quarterly Revenues; IVUS Disposable
Revenues Increase 46%
"This growth in our IVUS business occurred despite a sluggish global PCI
market. We believe the ease of use and integration provided by our s5 family
of consoles, along with a growing volume of data demonstrating the value of IVUS
in stenting procedures, is driving our increased market presence in the IVUS
arena," he added. "We are encouraged by what appear to be recent favorable
trends in stenting procedures and believe this will further the growth of our
IVUS offerings," he continued. (Read
more...)
February 7, 2008
Volcano
Announces FDA 510(k) Clearance of Revolution Rotational
Catheter and FFR for the s5i Integrated IVUS Console
These two new product offerings now enable rotational IVUS and FFR to
operate on the same integrated Volcano s5 Imaging System as Volcano's
previous line of phased array IVUS catheters and functionality. For the
first time, physicians can choose among three powerful diagnostic tools
-- all on the same integrated IVUS platform. (Read
more...)
December 10, 2007
Volcano
Announces Agreement to Acquire CardioSpectra
Volcano Corporatio, a provider of intravascular ultrasound (IVUS) and
functional measurement (FM) products designed to enhance the diagnosis
and treatment of vascular and structural heart disease, said today that
it has reached a definitive agreement to acquire CardioSpectra, Inc.,
a privately-held company developing innovative Optical Coherence Tomography
(OCT) technology. CardioSpectra's unique OCT imaging system is expected
to complement Volcano's existing product offerings and will further enhance
Volcano's position as an imaging technology leader in the field of interventional
medicine. (Read
more...)
November 8, 2007
Volcano
Reports Record Third Quarter Revenues
Volcano Corporation, a leading provider of intravascular ultrasound (IVUS)
and functional measurement (FM) products, today reported record revenues
of $31.5 million, a 13 percent increase over revenues of $27.8 million
in the third quarter a year ago. (Read
more...)
November 8, 2007
Cordis
Europe Partnering With Volcano Europe to Provide Access
to Intravascular Imaging (IVUS) for Use in Drug-Eluting
Stent Procedures
One of the major drug-eluting stent makers seems to agree with the idea
that intravascular ultrasound (IVUS) guidance is critical for the proper
placement of their devices. This move is a significant one for Volcano,
which has long been trying to educate the interventional cardiology community
about IVUS. (Read
more...)
October 22, 2007
Volcano
Announces Activities at TCT 2007: Expanded Role of IVUS
in PCI to be Demonstrated
Volcano Corporation, a leading manufacturer of intravascular ultrasound
(IVUS) and functional measurement (FM) technology, announced today activities
planned for the 2007 Transcatheter Cardiovascular Therapeutics (TCT)
conference that will take place from October 20th to October 25th in
Washington D.C. (Read
more...)
October 22, 2007
Volcano
Sponsors First Study Designed to Determine if IVUS Can
Identify Patients at Risk for Stent Thrombosis and to
Demonstrate the Benefit of IVUS Guidance for Procedural
Outcome
3,000 patients will be studied as part of a multi-center IVUS sub-study,
part of the Cardiovascular Research Foundation's ADAPT-DES Study to quantify
the causes and cures of thrombosis in drug-eluting stents. (Read
more...)
September 4, 2007
Volcano
Corporation Presentation at Bear Stearns Conference to
be Webcast
Volcano Corporation, a provider of intravascular ultrasound (IVUS) and
functional measurement (FM) products designed to enhance the diagnosis
and treatment of vascular and structural heart diseases, said today that
it will be participating in the Bear Stearns 2007 Healthcare Conference
on Tuesday, September 11. (Read
more...)
July 24, 2007
Volcano
Corporation Announces Japan Approval of the s5i Integrated
IVUS Platform
Volcano Corporation today announced approval of the s5i Integrated IVUS
System by necessary regulatory authorities in Japan, granting entry into
the Japanese market. Volcano expects to launch the s5i into Japan, which
represents the largest Intravascular Ultrasound (IVUS) market worldwide,
during the current quarter. (Read
more...)
May 30, 2007
Most
Heart Stents Are Placed Imperfectly, Increasing Risk
of Heart Attack or Reclosure
Results of a new study show that stent placement involves a "geographic
miss" two-thirds of the time, resulting in a three-fold increased
risk of heart attack and a two-fold increase in reintervention. The article
includes interviews with Dr. Marco Costa of the University of Florida
College of Medicine in Jacksonville, chief investigator for the S.T.L.L.R.
study, and Dr. Antonio Colombo of Columbus and San Raffaele Hospitals
in Milan, Italy (Read
more...)
May 7, 2007
Volcano
Corporation Reports 49 Percent Increase in Revenues;
IVUS Disposable Sales Increase 33 Percent
(source: Volcano Corporation)
Volcano Corporation, a leading provider of intravascular ultrasound (IVUS)
and functional measurement (FM) products designed to enhance the diagnosis
and treatment of vascular and structural heart diseases, today reported
that revenues in the first quarter of 2007 increased 49 percent over
revenues in the first quarter a year ago. (Read
more...)
April 25, 2007
Volcano
Corporation Schedules First Quarter Conference Call,
Webcast
(source: Volcano Corporation)
The company will hold a conference call to discuss its financial results
and operating activities to all interested parties at 2 p.m., Pacific
Daylight Time (5 p.m. Eastern Daylight Time), Monday, May 7, hosted by
Scott Huennekens, president and chief executive officer, and John Dahldorf,
chief financial officer. (Read
more...)
April 18, 2007
COURAGE,
SPIRIT Data May Support Role of Advanced Imaging and
Diagnosis With IVUS and FFR
(source: Volcano Corporation)
The results of recent studies presented at this year's American College
of Cardiology may support the role played by intravascular ultrasound
(IVUS) and fraction flow reserve (FFR) in diagnosing the need for stenting
more accurately than standard angiography and, when the use of a stent
is indicated, aiding in the accuracy of stent placement. (Read
more...)
April 4, 2007
Volcano
Corp. Reports Use of Intravascular Ultrasound (IVUS)
Increasing as Physicians Refocus on Stent Technique
While use in the United States of DES has decreased from 89% to an estimated
70% over the past year, driven by concerns over stent thrombosis causing
heart attacks, and confidence in Bare Metal Stent (BMS) safety, for the
same period, Volcano has seen an increase of 25% in IVUS revenue, demonstrating
more reliance on detailed imaging to guide optimal DES and BMS placement. (Read
more...)
April 3, 2007
Volcano
Corporation and ev3 Inc. Announce Joint Marketing and
Distribution Agreement
Under the terms of the agreement, Volcano will have the opportunity to
sell ev3's SpiderFX Embolic Protection Device in conjunction with their
Intravascular Ultrasound (IVUS) and Functional Measurement (FM) devices
for use in saphenous vein grafts (SVG's) in the U.S. (Read
more...)
February 13, 2007
Volcano
Corporation and Cordis Endovascular Japan Announces Distribution
Agreement for IVUS Indications
(source: Volcano Corporation)
Volcano Corporation today announced the signing of a distribution agreement
with Johnson & Johnson K.K., Medical Company.The agreement appoints
Cordis Endovascular Systems Japan as a distributor of IVUS products for
use in peripheral and endovascular procedures in Japan.
November 27, 2006
Intravascular
Ultrasound (IVUS) Imaging Technology May Help Lower Rates
of Late Stent Thrombosis
While there are a number of causes of late stent thrombosis that have
been identified, one of the factors most associated is poor apposition
(incomplete expansion or suboptimal positioning) of the drug-eluting
stent. A recent presentation by Dr. William Wijns of Aalst, Belgium at
last month's TCT meeting showed that in 77% of the late stent thrombosis
cases (clotting one year after implantation) the stent showed incomplete
apposition (mal-apposition was seen in only 12% of cases where there
was no stent thrombosis). (Read
more...)
November 13, 2006
Volcano
Announces Clinical Review of Key Presentations From TCT
2006
(source: Volcano Corporation)
The whole field of intravascular ultrasound (IVUS) is gaining in importance
as problems are surfacing about drug-eluting stents. The value of IVUS
October 20, 2006
Volcano
Corporation and MediGuide Ltd. Announce Collaboration
for Advanced Imaging and Navigation Technology
(source: Volcano Corporation)
The companies initially plan to develop Guided IVUS (GIVUS), a product
which will integrate MediGuide's Medical Positioning System (MPS) with
Volcano's intravascular ultrasound (IVUS) system. This combination of
technologies will expand the two dimensional aspect of the existing IVUS
image into a three dimensional image that is designed to provide more
useful clinical information, allow for easier interpretation of the image
by interventional cardiologists and improve the clinical utility of the
image.
October
11, 2006
Volcano
Announces First Permanent Installations of the
Integrated s5i IVUS Imaging System
(source: Volcano Corporation)
The company today announced the first permanent installations of the
s5i IVUS (intravascular ultrasound) imaging system in both the U.S. and
Europe. The s5i is Volcano's first IVUS system that can be integrated
into any new or existing cath lab configuration. Through a series of
customizable components, Volcano can now tailor an integrated IVUS solution
to the unique user and workflow needs for any vendor's cath lab type
or configuration.
August 24, 2006
GE
Healthcare and Volcano Corporation Announce FDA Clearance
of Fully-Integrated Intravascular Ultrasound Imaging
on the Innova Platform
(source: GE
Healthcare and
Volcano Corporation)
The FDA has given clearance to a new integrated state-of-the-art intravascular
ultrasound (IVUS) platform with an all-digital X-ray cath lab imaging
system. (Read
more...)
August 30, 2006
Abbott
Announces Completion of Enrollment in Groundbreaking
Vulnerable Plaque Study
Utilizing the Volcano Therapeutics' intravascular ultrasound imaging
system, the PROSPECT study, headed by Dr. Gregg Stone of Columbia University
Medical Center in New York, will attempt to more clearly define who is
at risk for a heart attack by looking at vulnerable plaque, not just
plaque "build-up". (Read
more...)
|